Catalent Inc., a Somerset-based drug delivery company, announced on Friday it has named Karen Flynn the president of biologics and chief commercial officer.
Flynn, who will be part of the company’s executive leadership team, is succeeding Barry Littlejohns, who is retirng, and will report to Alessandro Maselli, president and chief operating officer. She will be responsible for Catalent’s biologics business, including several current investments and expansions.
Flynn has more than 30 years of experience in commercial, operations and general management in the pharmaceutical industry, and she is rejoining Catalent after more than 11 years, previously spending eight years as part of Cardinal Health/Catalent in various roles. She most recently served as senior vice president and chief commercial officer for West Pharmaceutical Services.
“We welcome Karen back to Catalent in a role that allows her to use her extensive talents and experience as we deliver to our customers advanced, crucial pharmaceutical research and development services, as well as commercial supply,” Maselli said. “Karen arrives during a period of strong growth both in the biologics business and across the company as a whole, during which we are investing hundreds of millions of dollars in our biologics business and strengthening our commitment to ensuring that our customers have access to the best possible advanced biologic development technology and manufacturing solutions, from DNA through to clinical and commercial supply.”
In addition, the company announced Mike Riley has been promoted to region president, biologics North America and appointed Manja Boerman as region president, biologics Europe, leading biologics, development, manufacturing and commercial activity in their regions. Riley, who’s been with Catalent for 15 years, previously served as vice president, general manager of Catalent Biologics. Boerman joined in December 2019 after serving as president of Aesica Pharmaceuticals. They both will report directly to Flynn.
